Invivyd (IVVD) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Invivyd

NasdaqGM•Healthcare•Biotechnology

$0.81-0.02(-0.03%)Pre-market

Market Cap

$242.02M

P/S

4.1x

P/B

1.3x

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.

How this company scores

AverageMetricSide Score: 57/100

Strongest: Growth (20/25); weakest: Cash & Earnings Quality (10/25).

Profitability12/25

Growth20/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality10/25

Strengths

Growing revenueInterest easily coveredCash-backed earningsProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 4.1x5y range 1.9x – 58.0x

Currently near its 9-quarter median.

P/B · 1.3x5y range 0.4x – 3.9x

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $242.02M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $58.37M
Q. Revenue: $14.29M
TTM EBITDA: $-112.53M
TTM Op. Income: $-112.53M
Q. Op. Income: $-45.82M
TTM Net Income: $-107.33M
Q. Net Income: $-44.39M
EPS: $-0.14
Shares Out.: $320.44M

$58.37M in TTM revenue grew 26.3% YoY, reaching $14.29M last quarter. TTM EBITDA of $-112.53M and TTM operating income of $-112.53M show growth is flowing through to the bottom line. However, net income is negative at $107.33M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -320.8%
Op. Margin: -320.8%
Net Margin: -310.8%

Op. margin of -320.8% is down 193.0% YoY — costs are rising relative to revenue. Net margin at -310.8% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 4.1x
P/B Ratio: 1.3x

P/S of 4.1x and P/B of 1.3x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $218.88M
Cash: $160.08M
Long-Term Debt: N/A
Book Value: $181.08M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-43.01M
TTM Free Cash Flow: $-109.66M
FCF Margin: -187.9%
FCF / Net Income: 1.0

TTM FCF of $-109.66M on $-43.01M in operating cash flow. The FCF / Net Income ratio of 1.0x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.